Is DTIL or ENGN more undervalued in 2026?

CirclFi compares Precision BioSciences, Inc. (DTIL) and enGene Therapeutics Inc. (ENGN) using 13 institutional-grade valuation models. DTIL has a Quality of Company score of 5.6/10 while ENGN scores 4.1/10.

Which is a better buy — DTIL or ENGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DTIL and ENGN valuations compare?

DTIL at $6.97 and ENGN at $1.85 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DTIL vs ENGN Valuation Comparison 2026 — Intrinsic Value Analysis

DTIL

Biological Products, (No Diagnostic Substances)

Precision BioSciences, Inc.

Quality

5.6

out of 10

Value Trap

SAFE

Price

$6.97

Last close

Models

9/13

Active

ENGN

Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$1.85

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	DTIL Fair Value	DTIL Upside	ENGN Fair Value	ENGN Upside
Bayesian DCF	Intrinsic	$3.93	-43.7%	$0.54	-70.9%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.10	-98.6%	$1.93	+4.2%
Dynamic NAV	Asset-Based	$2.65	-62.0%	$3.11	+68.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DTIL vs ENGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DTIL vs ENGN — Which Stock Is More Undervalued?

DTIL scores higher with a 5.6/10 quality rating vs ENGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Precision BioSciences, Inc. (DTIL) and enGene Therapeutics Inc. (ENGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DTIL currently trades at $6.97 with a QOC of 5.6/10, while ENGN trades at $1.85 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).